CD93 and liver dysplastic nodule: Considering the subgroup that shows early development and rapid progression of DN even under similar glycemic control, blood pressure, and lipid control status [26,27], identifying the unique population for high sCD93 and evaluating the mechanism of CD93/sCD93 modulation would provide further clinical implications for DN prevention and treatment.